Get the Stockscreener App
18.16
7.35%
-1.44
After Hours:
18.23
0.07
+0.39%
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study - The Bakersfield Californian
Can Acadia's New Essential Tremor Drug Candidate Survive Its Clinical Trial Pause? - StockTitan
Acadia Pharmaceuticals Ends FY2024 On Solid Footing (NASDAQ:ACAD) - Seeking Alpha
FY2025 EPS Estimates for ACAD Decreased by Cantor Fitzgerald - MarketBeat
Brokers Issue Forecasts for ACAD Q1 Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Phocas Financial Corp. - MarketBeat
Los Angeles Capital Management LLC Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Sells 773 Shares of Stock - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 6.4%Should You Buy? - MarketBeat
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highligh - GuruFocus.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... By GuruFocus - Investing.com Canada
Allspring Global Investments Holdings LLC Reduces Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals Reports Strong Earnings and Growth Plans - TipRanks
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference - BioSpace
ACADIA PHARMACEUTICALS INC SEC 10-K Report - TradingView
ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Can Acadia's Neuroscience Innovations Impress Investors at TD Cowen Healthcare Conference? - StockTitan
Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews - Benzinga
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth - MSN
Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2024 Earnings Call Transcript - Insider Monkey
Acadia: Q4 Earnings Snapshot - Thehour.com
Acadia Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
ACADIA Pharmaceuticals: Strong Financial Performance and Growth Prospects Justify Buy Rating - TipRanks
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - BioSpace
Acadia Pharmaceuticals Q4 EPS, Revenue Rise -February 26, 2025 at 05:41 pm EST - Marketscreener.com
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates - Yahoo Finance
Earnings Flash (ACAD) Acadia Pharmaceuticals Reports Q4 Revenue $259.6M, vs. FactSet Est of $255.6M - Marketscreener.com
Acadia Pharmaceuticals CFO sells shares worth $15,429 By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals principal accounting officer sells shares worth $9,481 - Investing.com India
Acadia Pharma Q4 2024 Earnings Preview - MSN
ACADIA Pharmaceuticals CFO Sells Shares to Cover Taxes - TradingView
How the (ACAD) price action is used to our Advantage - Stock Traders Daily
Director Commercial Launch Excellence and PlanningAcadia Pharmaceuticals Inc. - Built In
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
ACADIA Pharmaceuticals (ACAD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
JP Morgan Week 2025 – Catherine Owen Adams - pharmaphorum
ACADIA Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 5.2% in January - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 14, 2025 - BioSpace
Acadia Pharmaceuticals Turns Heads with Ambitious Stock Awards - mivalle.net.ar
Biotech Giant Acadia Pharmaceuticals Lures Talent with Slick New Stock Incentives - Jomfruland.net
ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Talent Expansion: Acadia Pharmaceuticals Secures 18 Key Hires with Strategic Equity Package - StockTitan
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? - MSN
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy' - Seeking Alpha
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Deutsche Bank Initiates Coverage of ACADIA Pharmaceuticals (ACAD) with Hold Recommendation - MSN
Acadia's Q4 Results Coming: Major Updates on Breakthrough Parkinson's and Rett Syndrome Treatments - StockTitan
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):